Sartorius AGSARTF 84 Return-on-Tangible-Asset is 4.96% as of Mar. 2026, which is 52% below its 10-year median of 10.39. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $273.33 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Sartorius AG ranks better than 63.67% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sartorius AG's annualizedNet Income for the quarter that ended in Mar. 2026 was $260 Mil. Sartorius AG's average total tangible assets for the quarter that ended in Mar. 2026 was $5,237 Mil. Therefore, Sartorius AG's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 4.96%.
The historical rank and industry rank for Sartorius AG's Return-on-Tangible-Asset or its related term are showing as below:
SARTF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.89 Med: 10.39 Max: 18.79
Current: 4.4
During the past 13 years, Sartorius AG's highest Return-on-Tangible-Asset was 18.79%. The lowest was 1.89%. And the median was 10.39%.
SARTF's Return-on-Tangible-Asset is ranked better than 63.67% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs SARTF: 4.40
Sartorius AG (OTCPK:SARTF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sartorius AG Return-on-Tangible-Asset Related Terms
Sartorius AG Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.96% mean?
Sartorius AG (SARTF) has a Return-on-Tangible-Asset of 4.96% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sartorius AG and its competitors. This is 52% below median its historical median of 10.39. Over the past decade, Sartorius AG's Return-on-Tangible-Asset has ranged from 1.89 to 18.79. According to the industry distribution chart, Sartorius AG ranks #311 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 36.3%.
Is Sartorius AG's Return-on-Tangible-Asset too high?
Sartorius AG's current Return-on-Tangible-Asset of 4.96% is 52% below median its 10-year median of 10.39. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 18.79. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Sartorius AG's value of 4.96% is 733.6% above this industry median. Based on the distribution chart, Sartorius AG ranks #311 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #311 out of 856 companies for Return-on-Tangible-Asset. This puts Sartorius AG in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Sartorius AG's value of 4.96% is 733.6% above this benchmark. Historically, Sartorius AG's own Return-on-Tangible-Asset has ranged from 1.89 to 18.79 over the past decade. While the company's 10-year median is 10.39 vs. the industry median of 0.60, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Return-on-Tangible-Asset of 4.96% is 733.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Return-on-Tangible-Asset is 4.96%, which is 52% below median its own 10-year median of 10.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.33, compared to a current price of $212.80 — trading 22.1% below its estimated fair value. The current Return-on-Tangible-Asset is 4.96%, which is 52% below median its 10-year median of 10.39 and 733.6% above the Medical Devices & Instruments industry median of 0.60. Sartorius AG's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Return-on-Tangible-Asset is 4.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.1% below its estimated GF Value™ of $273.33.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Return-on-Tangible-Asset: 4.96% (52% below median its 10-year median of 10.39)
GF Value™: $273.33 vs. price of $212.80 (22.1% below fair value)
Industry Position: 733.6% above the Medical Devices & Instruments median (#311 of 856)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
